1 – 10 of 67
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2023
-
Mark
Burden of established cardiovascular disease in people with type 2 diabetes and matched controls : Hospital-based care, days absent from work, costs and mortality
(
- Contribution to journal › Article
- 2022
-
Mark
Model-based predictions on health benefits and budget impact of implementing empagliflozin in people with type 2 diabetes and established cardiovascular disease
2022) In Diabetes, Obesity and Metabolism(
- Contribution to journal › Article
- 2021
-
Mark
Interaction of diabetes genetic risk and successful lifestyle modification in the Diabetes Prevention Programme
(
- Contribution to journal › Article
-
Mark
The majority of people with type 1 diabetes and multiple daily insulin injections benefit from using continuous glucose monitoring : An analysis based on the GOLD randomized trial (GOLD-5)
(
- Contribution to journal › Article
- 2020
-
Mark
Persistent whole day meal effects of three dipeptidyl peptidase-4 inhibitors on glycaemia and hormonal responses in metformin-treated type 2 diabetes
(
- Contribution to journal › Article
-
Mark
Peptide YY (1–36) peptides from phylogenetically ancient fish targeting mammalian neuropeptide Y1 receptors demonstrate potent effects on pancreatic β-cell function, growth and survival
(
- Contribution to journal › Article
-
Mark
Days absent from work as a result of complications associated with type 2 diabetes : Evidence from 20 years of linked national registry data in Sweden
(
- Contribution to journal › Article
- 2019
-
Mark
Metformin is the key factor in elevated plasma growth differentiation factor-15 levels in type 2 diabetes : A nested, case–control study
(
- Contribution to journal › Article
-
Mark
Association between diabetic eye disease and other complications of diabetes : Implications for care. A systematic review
(
- Contribution to journal › Scientific review
-
Mark
Investigating optimal β-cell-preserving treatment in latent autoimmune diabetes in adults : Results from a 21-month randomized trial
(
- Contribution to journal › Article